{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T07:31:39Z","timestamp":1782891099716,"version":"3.54.5"},"reference-count":10,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.medcli.2020.06.013","type":"journal-article","created":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T13:01:02Z","timestamp":1593090062000},"page":"488-490","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors"],"prefix":"10.1016","volume":"155","author":[{"given":"Rafael","family":"Golpe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis A.","family":"P\u00e9rez-de-Llano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dacal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector","family":"Guerrero-Sande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Pombo-Vide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Ventura-Valc\u00e1rcel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2020.06.013_bib0055","doi-asserted-by":"crossref","unstructured":"Guan W, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: a nationwide analysis Eur Respir J. In press. DOI: 10.1183\/13993003.00547-2020.","DOI":"10.1183\/13993003.00547-2020"},{"key":"10.1016\/j.medcli.2020.06.013_bib0060","doi-asserted-by":"crossref","unstructured":"Li G, Hu R, Zhang X. Antihypertensive treatment with ACEI\/ARB of patients with Covid-19 complicated by hypertension. Hypertens Res. In press. DOI: 10.1038\/s41440-020-0433-1.","DOI":"10.1038\/s41440-020-0433-1"},{"key":"10.1016\/j.medcli.2020.06.013_bib0065","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S2213-2600(20)30116-8","article-title":"Are patients with hypertension and diabetes mellitus at increased risk for Covid-19 infection?","volume":"8","author":"Fang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.medcli.2020.06.013_bib0070","unstructured":"Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MD, Solomon SD. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med. In press. DOI: 10.1056\/NEJMsr 2005760."},{"key":"10.1016\/j.medcli.2020.06.013_bib0075","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/22221751.2020.1746200","article-title":"Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension","volume":"9","author":"Meng","year":"2020","journal-title":"Emerging Microbes & Infections"},{"key":"10.1016\/j.medcli.2020.06.013_bib0080","doi-asserted-by":"crossref","unstructured":"Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, et al. Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19. Circ Res. In press. DOI: 10.1161\/CIRCRESAHA.120.317134.","DOI":"10.1161\/CIRCRESAHA.120.317134"},{"key":"10.1016\/j.medcli.2020.06.013_bib0085","doi-asserted-by":"crossref","unstructured":"Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in Covid-19. New Engl J Med. In press. DOI: 10.1056\/NEJMoa2007621.","DOI":"10.1056\/NEJMoa2007621"},{"key":"10.1016\/j.medcli.2020.06.013_bib0090","doi-asserted-by":"crossref","unstructured":"Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, et al. Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19. N Engl J Med. In press. DOI: 10.1056\/NEJMoa2008975.","DOI":"10.1056\/NEJMoa2008975"},{"key":"10.1016\/j.medcli.2020.06.013_bib0095","doi-asserted-by":"crossref","unstructured":"Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-angiotensin-aldosterone system blockers and the risk of Covid-19. N Engl J Med. In press. DOI: 10.1056\/NEJMoa2006923.","DOI":"10.1056\/NEJMoa2006923"},{"key":"10.1016\/j.medcli.2020.06.013_bib0100","doi-asserted-by":"crossref","unstructured":"Kuster GM, Pfister O, Burkard T, Zhou Q, Twerenbold R, Haaf P, et al. SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with Covid-19? Eur Heart J. In press. https:\/\/doi: 10.1093\/eurheartj\/ehaa235.","DOI":"10.1093\/eurheartj\/ehaa235"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775320304024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775320304024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T19:49:24Z","timestamp":1607370564000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775320304024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0025775320304024"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2020.06.013","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2020.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}